No Data
Can-Fite BioPharma Files to Sell 3.29M Ordinary Shares for Holders
Can-Fite BioPharma Partners With Vetbiolix in $325M Deal for Canine Osteoarthritis Treatment Development
Can-Fite BioPharma | 20-F: FY2025 Annual Report
Can-Fite BioPharma Posts 2025 Loss but Highlights Long-Term Cancer Survival and Clinical Progress
Can-Fite BioPharma | 6-K: Report of foreign private issuer (related to financial reporting)
Can-Fite BioPharma Ltd. Reports Clinical Advancements and Financial Results for 2025

